Related Experiment Video
Updated: May 8, 2026

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
Published on: January 25, 2016
[A Meta-analysis of prothrombin G20210A polymorphism and its risk for sudden sensorineural hearing loss]
Bo Liu1, Wen-jing Feng, Xiao-xia Peng
1Department of Otorhinolaryngology Head and Neck Surgery, Capital Medical University, Beijing, China. trliubo@139.com
Objective:
To investigate the correlation between prothrombin G20210A polymorphism and the risk for idiopathic sudden sensorineural hearing loss (ISSNHL) using Meta-analysis methodology.
Methods:
Databases, including PUBMED, EMBASE, Cochrane Library and CBM, were searched to collect the case control studies on the correlation between prothrombin G20210A polymorphism and idiopathic sudden sensorineural hearing loss. Only high quality studies were included. All analysis were conducted with Review Manager Version 4.2 software.
Results:
A total of 9 studies were included, involving 735 cases and 1230 controls. The quality assessment involved 3 parts, 8 scores (totally 8 stars). The results showed the included studies were high-quality. Two studies were 8 stars of quality, three studies were 7 stars, one study was 6 stars, one study was 5 stars, and two studies were 4 stars. Meta-analysis showed that the prothrombin G20210A mutation frequencies of the genotypes and alleles showed significant statistically difference between cases and controls [P = 0.03, OR = 1.79, 95% CI = (1.06, 3.01); P = 0.03, OR = 1.77, 95% CI = (1.06, 2.97), respectively].
Conclusions:
The prothrombin G20210A polymorphism might be a genetic risk factor for sudden hearing loss. However, this conclusion remains to be confirmed by high-quality, large-scale studies.
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

